Pure Global
NCT02007772

Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD Patients

Effectiveness of TNI (Nasal High-flow) vs. BiPAP (Biphasic Positive Airway Pressure) in Chronic Global Insufficiency in COPD (Chronic Obstructive Pulmonary Disease) Patients
University of Leipzig·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
COPD Chronic Obstructive Pulmonary Disease
Drug/Device/Intervention
nHF
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
University of Leipzig
Location
Donaustauf,Muenchen-Gauting,Nürnberg,Rosenheim,Kassel,Bovenden,Schmallenberg,Solingen,Leipzig,Bad Berka,Bergisch Gladbach,Berlin,Hamburg,Wangen im Allgäu, Germany
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2011
End date
Jul 01, 2017
Enrollment
105 participants
Primary outcome

difference in capillary CO2 carbon dioxide

Summary

The purpose of this trial ist to investigate the difference of the efficacy of two systems
 for breath support in patients with COPD.

ICD-10 classifications
Other chronic obstructive pulmonary diseaseOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02007772
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT02007772 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Leipzig and is currently Completed. The study focuses on COPD Chronic Obstructive Pulmonary Disease. Target enrollment is 105 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.